⚠ Evidence warning: Clinical trials or other evidence do not support the quoted figures of about 40% idiopathic cases, 200–600 cases per 100,000 men, 5,000–15,000 new United States cases a year and 80–90% graft-repair success at 10 years. This page keeps it as a report of what people, websites or other media say.

Urethral Stricture

Table of Contents

  1. Overview
  2. Epidemiology
  3. Anatomy and Classification
  4. Etiology
  5. Pathophysiology
  6. Diagnosis
  7. Treatment
  8. Outcomes
  9. Complications
  10. Special Considerations
  11. Recent Research
  12. Key Research Papers
  13. Connections
  14. Featured Videos

1. Overview

Urethral stricture is a fibrotic narrowing of the urethra caused by scar tissue formation within or surrounding the urethral lumen, reducing its diameter and impeding urine flow. The condition predominantly affects the male urethra — the longer, more anatomically complex male urinary channel is far more vulnerable to the traumatic, iatrogenic, and inflammatory injuries that drive stricture formation. The bulbar urethra is the most frequently affected segment, followed by the penile and membranous urethra.

The defining pathology is spongiofibrosis — replacement of the normally elastic corpus spongiosum tissue surrounding the urethra with dense, inelastic fibrous scar. Patients develop obstructive lower urinary tract symptoms (LUTS): a weak, intermittent stream, prolonged voiding, straining, incomplete bladder emptying, post-void dribbling, and in severe cases acute urinary retention. An incidence of 200–600 per 100,000 males is an estimate with no named study behind it; a 2007 United States burden analysis (Santucci) states that the incidence of urethral stricture disease in the United States is unknown.

Female urethral stricture is a distinct and rare entity, often underdiagnosed because the short female urethra is less susceptible to scar-forming injuries and symptoms overlap with overactive bladder and recurrent urinary tract infection (UTI). When present in women it is usually iatrogenic (prior urethral surgery or catheterization) or lichen sclerosus-related.

2. Epidemiology

A 2007 United States analysis (Santucci) found urethral stricture at a rate as high as 0.6% in some susceptible populations, and the 2020 report of a United Kingdom trial (OPEN) gives 0.9% of men. True prevalence is likely higher because many men with mild obstructive symptoms do not seek evaluation. Two age peaks are described:

Measured data come from one referral center's 1,439 men operated on from 2000 to 2010 (Palminteri 2013): 92.2% of strictures were anterior and 7.8% posterior; 46.9% were bulbar and 30.5% penile. Cases rose until about age 45 and then fell, were uncommon under 20 and over 70, and the mean stricture length was 4.15 cm. The authors conclude that the disease is not one of the elderly but involves all ages.

The etiology landscape has shifted substantially in the 21st century. Gonorrhea-related stricture, historically one of the most common causes, has become rare in developed countries with effective antibiotic treatment. Idiopathic stricture — where no specific cause can be identified despite thorough evaluation — has been quoted at approximately 40% of cases in developed-world series. The measured series read are lower: unknown cause in 35.8% of 1,439 men (Palminteri 2013) and about 1 in 3 of 268 men (Lumen 2009). Iatrogenic causes (those from medical procedures) were the largest group in both, at 38.6% and 45.5%; idiopathic stricture leads only when each iatrogenic cause is counted separately. Iatrogenic causes account for 35–45% and are increasing as urological procedure volumes grow. An estimate of 5,000–15,000 new United States cases per year requiring procedural intervention has no named study behind it; the Santucci analysis reports more than 5,000 inpatient visits yearly and almost 1.5 million office visits yearly between 1992 and 2000.

3. Anatomy and Classification

A thorough understanding of urethral anatomy is essential to understanding stricture disease:

Anatomic Segments

Anterior vs. Posterior Stricture

The most clinically important anatomic distinction is between anterior stricture (meatal through bulbar urethra — the most common) and posterior stricture (membranous and prostatic urethra, typically post-pelvic fracture urethral injury or post-radical prostatectomy anastomotic stenosis). These two categories have different mechanisms, management approaches, and surgical techniques.

Spongiofibrosis

The extent of spongiofibrosis — the fibrotic replacement of the corpus spongiosum — is the single most important determinant of surgical approach and outcome. Superficial (mucosal-only) strictures respond well to internal urethrotomy; strictures with dense, deep spongiofibrosis extending into the surrounding erectile tissue require formal urethroplasty. Magnetic resonance imaging (MRI) urethrogram with spongiofibrosis mapping guides surgical planning for complex cases.

Classification Systems

The American Urological Association (AUA) and European Association of Urology (EAU) classify strictures by length (short: <2 cm; moderate: 2–4 cm; long: >4 cm), location, etiology, and depth of spongiofibrosis. This multi-parameter classification guides treatment selection more reliably than any single variable.

4. Etiology

Urethral stricture arises from four major etiologic categories. The percentages in the headings below are approximate and can add to more than 100%; among the 1,439 men in Palminteri 2013 the shares were iatrogenic 38.6%, unknown 35.8%, lichen sclerosus 13.4% and trauma 10.8%.

Traumatic (15–20%)

Iatrogenic (35–45%)

Inflammatory (15–20%)

Idiopathic (quoted at ~40%; 35.8% in Palminteri 2013)

A substantial proportion of strictures — particularly short, isolated bulbar strictures — have no identifiable etiology despite thorough history and investigation. These may represent forgotten childhood perineal trauma, subclinical episodes of urethritis, or as-yet-uncharacterized genetic susceptibility to fibrotic remodeling of the corpus spongiosum.

5. Pathophysiology

The final common pathway of all urethral strictures is progressive collagen deposition replacing the normal elastic architecture of the corpus spongiosum. The sequence unfolds in several overlapping phases:

Initial Injury

Whether from blunt trauma, catheter erosion, instrumentation, infection, or ischemia, the initial insult disrupts the urethral epithelium and subepithelial vasculature. In trauma, extravasation of blood and urine into the corpus spongiosum initiates an intense inflammatory cascade.

Inflammatory Response and Fibroblast Activation

Macrophage infiltration, mast cell degranulation, and cytokine release (transforming growth factor beta 1 (TGF-beta1), interleukin-6 (IL-6), platelet-derived growth factor (PDGF)) activate resident fibroblasts and recruit circulating fibrocytes. Transforming growth factor beta 1 is the master regulator of urethral stricture fibrosis — it drives fibroblast-to-myofibroblast differentiation, upregulates collagen I and III synthesis, and suppresses matrix metalloproteinase (MMP) activity, tipping the balance toward extracellular matrix accumulation.

Spongiofibrosis

Progressive replacement of the normally elastic spongiosal erectile tissue with dense, inelastic Type I collagen produces the pathognomonic spongiofibrosis of urethral stricture. The affected segment becomes hard, avascular, and non-compliant. The degree of spongiofibrosis determines luminal narrowing severity, length of disease, and response to treatment — superficial spongiofibrosis responds to endoscopic incision, while dense deep fibrosis extending to the tunica albuginea of the corpus cavernosum requires tissue excision or augmentation.

Lichen Sclerosus Mechanism

Lichen sclerosus follows a distinct autoimmune pathway. CD4+ and CD8+ T-lymphocytes infiltrate genital skin and underlying dermis, producing lichenoid tissue destruction, subepidermal homogenization, and progressive dermal fibrosis. The urethra is involved when disease extends from the preputial skin into the meatus and beyond. Unlike traumatic stricture, LS-associated spongiofibrosis is driven by active immune dysregulation rather than wound repair — explaining why skin grafts harvested from affected or at-risk genital skin invariably develop LS themselves and fail.

Consequences of Obstruction

Progressive luminal narrowing elevates voiding pressure. The detrusor compensates initially through hypertrophy (trabeculation) but ultimately decompensates, leading to elevated post-void residual, incomplete bladder emptying, and — in severe or untreated cases — bilateral hydroureteronephrosis and renal impairment.

6. Diagnosis

A systematic evaluation establishes stricture presence, location, length, etiology, and severity — all necessary for treatment planning.

Symptom Assessment

Uroflowmetry

A non-invasive office test measuring urine flow rate. Stricture produces a characteristic plateau (box-shaped) flow pattern with peak flow rate (Qmax) typically below 10 mL/s and often below 5 mL/s in significant strictures. A normal Qmax (>15 mL/s with adequate voided volume) effectively excludes clinically significant obstruction.

Post-Void Residual (PVR)

Bladder ultrasound after voiding quantifies incomplete emptying. Elevated PVR (>100 mL persistently) indicates significant obstruction or detrusor dysfunction and guides urgency of intervention.

Retrograde Urethrogram (RUG)

The gold standard anatomic study for anterior urethral stricture. Contrast is injected retrogradely through the meatus under fluoroscopic guidance, opacifying the urethra from meatus to the stricture point. RUG defines stricture location, length, caliber, and number of strictures. Its limitation is inability to assess the proximal urethra beyond the stricture.

Voiding Cystourethrogram (VCUG)

Contrast is instilled into the bladder (via suprapubic puncture or catheter bypass) and the patient voids under fluoroscopy. VCUG delineates the proximal extent of a stricture and is essential for evaluating posterior urethral strictures and PFUI — the gap length between the two urethral ends determines surgical complexity and approach.

Urethroscopy / Flexible Cystoscopy

Direct endoscopic visualization of the urethra assesses mucosal appearance, stricture caliber, multiplicity, and the presence of lichen sclerosus (white, atrophic, inelastic mucosa) or inflammatory changes. Urethroscopy is complementary to imaging, not a replacement for RUG.

Magnetic Resonance Imaging Urethrogram

High-resolution pelvic magnetic resonance imaging with urethral distension (saline instilled retrogradely) precisely maps the depth and radial extent of spongiofibrosis beyond what fluoroscopic imaging can show. Increasingly used in complex or recurrent strictures to guide surgical planning — particularly the choice between excision and primary anastomosis versus augmentation with buccal mucosa graft.

7. Treatment

Treatment is selected based on stricture length, location, depth of spongiofibrosis, etiology, prior treatment history, and patient factors (surgical fitness, preference, anatomy). The therapeutic spectrum ranges from temporizing office procedures to definitive reconstructive surgery.

Dilation

Sequential passage of progressively larger bougies or hydrophilic dilators stretches the scar, temporarily enlarging the lumen. Dilation is an office procedure — technically straightforward, requires no anesthesia, and provides prompt symptom relief. However, it does not address the underlying fibrosis. Recurrence rates reach 70–80% within 12 months. Dilation is appropriate as a temporizing measure, for patients unfit for surgery, or for long-term maintenance in complex strictures not amenable to repair. Regular self-dilation (taught to the patient) can maintain patency between definitive treatments.

Direct Vision Internal Urethrotomy (DVIU)

Endoscopic cold-knife or laser incision of the stricture under direct cystoscopic vision releases the fibrotic scar and allows the lumen to re-epithelialize at a wider diameter. DVIU is most appropriate for short (<2 cm), primary (never previously treated), bulbar strictures without significant spongiofibrosis. Under these optimal conditions, success rates of 50–60% at one year are often quoted, and the OPEN trial report states that approximately half of strictures recur within 4 years. Long-term series report less: in 76 men with simple strictures, the stricture-free rate after a first urethrotomy was 8%, with a median time to recurrence of 7 months (Santucci and Eisenberg 2010); in 224 men followed for a median of 98 months, recurrence after one urethrotomy was 68% overall, 58% for bulbar and 84% for penile strictures (Pansadoro and Emiliozzi 1996). For longer strictures, multiple prior urethrotomies, or dense spongiofibrosis, success falls to 10–20%. A single DVIU attempt is reasonable for eligible patients; repeat DVIU is rarely curative and delays definitive reconstruction.

Urethroplasty (Definitive Reconstruction — Gold Standard)

Open surgical reconstruction of the urethra offers the highest and most durable success rates for most stricture types:

How Open Surgery and Repeat Cutting Compare for Recurrent Strictures

A United Kingdom randomized trial (OPEN, 222 men with a recurrent bulbar stricture) compared open urethroplasty with endoscopic urethrotomy. Both improved voiding symptoms to a similar degree over 24 months (mean difference -0.36 on the voiding symptom score, 95% confidence interval -1.74 to 1.02), but the benefit lasted longer after open surgery: 15 men needed another procedure, against 29 after urethrotomy (hazard ratio 0.52, 95% confidence interval 0.31–0.89). The primary analysis included only 63% and 81% of those allocated. A companion cost analysis found urethroplasty cost on average £2,148 more with a similar gain in quality-adjusted life years over 24 months, a 10-year model gave similar results, and the authors judged urethrotomy cost-effective.

Repair Without Fully Cutting the Spongy Tissue

A bulbar repair can be done without fully cutting across the spongy tissue around the urethra (non-transecting urethroplasty). A 2023 meta-analysis of 19 studies compared it with the standard transecting repair. Stricture recurrence was similar (risk ratio 1.06, 95% confidence interval 0.82–1.36), penile complications were lower with the non-transecting repair (risk ratio 0.47, 95% confidence interval 0.28–0.76), and the difference in erectile dysfunction was not statistically significant (risk ratio 0.73, 95% confidence interval 0.49–1.08).

Perineal Urethrostomy

Creation of a permanent perineal urethral opening allows voiding without passing through the strictured urethra. Appropriate for patients with recurrent panurethral disease, failed multiple urethroplasties, or who cannot undergo further reconstruction. Highly effective at relieving obstruction and acceptable to many patients who have suffered years of recurrent procedures.

8. Outcomes

Success rates in urethral stricture surgery depend critically on technique, stricture characteristics, and how "success" is defined (symptom-based, uroflow-based, or stricture-free by imaging):

Most failures come early, and the figures depend on how success is measured. Where any later instrument use counted as failure, 96.8% of the failures after 359 one-stage substitution repairs came within the first 5 years (Barbagli 2014). Stricture-free survival after 443 urethroplasties of all types was 88%, 82% and 79% at 1, 3 and 5 years (Breyer 2010). Urethrotomy series explain why repeat cutting is viewed poorly: success was no higher than 9% for a first or any later urethrotomy in one series (Santucci and Eisenberg 2010), and repeated urethrotomies did not improve the success rate in another (Pansadoro and Emiliozzi 1996).

A validated patient-reported outcome instrument — the PROM-USS, also written USS-PROM, defined by Jackson and colleagues in 2011 — captures symptom relief and quality-of-life recovery beyond objective patency measures and is increasingly required in contemporary trials. Long-term follow-up with uroflowmetry and symptom scoring is essential, as recurrence may be silent initially.

Self-catheterization as maintenance: In patients who have undergone urethroplasty and remain at high recurrence risk (radiation strictures, LS), periodic calibration with a small urethral catheter (self-intermittent catheterization, SIC) may detect and prevent asymptomatic recurrence before complete re-stricturing.

9. Complications

Complications of the Stricture Itself

Complications of Treatment

10. Special Considerations

Lichen Sclerosus (BXO)

LS-associated strictures deserve special mention because they violate the usual treatment hierarchy. Key management principles: (1) Genital skin grafts are absolutely contraindicated — LS will affect any graft harvested from genital skin, causing predictable graft failure. (2) Buccal mucosal graft (oral mucosa is immunologically unaffected by LS) is the tissue of choice for reconstruction. (3) For panurethral LS with obliteration from meatus to bulb, staged Johanson urethroplasty with BMG is the definitive approach. (4) Topical corticosteroids (clobetasol propionate) control skin disease but do not reverse established urethral fibrosis. (5) Circumcision is required as part of staged repair when the prepuce is involved.

Pelvic Fracture Urethral Injury (PFUI)

The management of PFUI has evolved substantially. Immediate primary repair at the time of injury was largely abandoned because of unacceptably high rates of impotence and incontinence. Current standard of care: (1) Suprapubic cystostomy for urinary diversion at time of injury. (2) Delayed urethroplasty at 3–6 months after complete hematoma resolution and pelvic ring stabilization. (3) Perineal approach EPA through the perineum is feasible in the majority of PFUI cases, even with defect lengths of 2–3 cm, through corporal separation and inferior pubectomy maneuvers. Long-term success rates of 90% are achievable with experienced surgeons.

Radiation Strictures

Strictures following prostate radiation (external beam radiation therapy or brachytherapy) are among the most challenging to manage because the entire perineal tissue bed is hypovascular, hypoxic, and fibrotic. Key points: (1) High recurrence rates after standard urethroplasty. (2) Vascularized tissue transfer (gracilis muscle flap) may be needed to provide healthy tissue coverage. (3) Perineal urethrostomy is a pragmatic option for men unwilling to accept high recurrence rates from multiple attempts at reconstruction.

Pediatric Urethral Stricture

In children, the most common cause of urethral stricture is hypospadias repair complications — anastomotic stricture at the neomeatus or fistulization along the reconstructed urethra. Surgical complexity is compounded by limited tissue availability in small children and the potential for ongoing growth affecting repair geometry. Post-traumatic stricture from straddle injury or instrumentation occurs but is less common in the pediatric age group than in adults.

11. Recent Research

Augmented anastomotic urethroplasty: Combining EPA with a dorsal BMG onlay allows repair of strictures up to 4–5 cm that would require more extensive grafting alone, with early series reporting success rates comparable to standard EPA. Guralnick and Webster (2001) reported 29 patients with this kind of repair, using a dorsal or ventral onlay (mean stricture length 1.5 cm, mean onlay length 4.5 cm): 27 of 29 (93%) were stricture-free at a mean of 28 months.

Urethral tissue engineering: Cell-seeded scaffolds combining acellular collagen matrices with autologous urothelial and smooth muscle cells have produced functional neourethras in animal models and small human pilot studies. Clinical translation faces challenges of manufacturing scale, regulatory hurdles, and long-term mechanical durability.

Laser versus cold knife DVIU: Trials comparing holmium:YAG laser urethrotomy to cold knife DVIU have been reported as finding equivalent success rates for primary short bulbar strictures, challenging the theoretical advantage of laser precision in reducing collateral thermal damage. A 2024 meta-analysis of nine comparative studies found no statistically significant difference in recurrence (risk ratio 0.71, 95% confidence interval 0.48–1.06), a trend rather than proof of equivalence, and less bleeding with laser (risk ratio 0.21, 95% confidence interval 0.08–0.53).

Paclitaxel-coated balloon: A dilating balloon coated with the drug paclitaxel stretches the stricture and delivers the drug locally. In a randomized, single-blind trial of 127 men with recurrent anterior strictures of 3 cm or less and at least 2 prior endoscopic treatments, the opening held at 6 months in 75%, against 27% with standard endoscopic treatment. At 3 years 71% of the treated group had needed no further procedure; the most frequent side effects were urinary tract infection, blood in the urine and painful urination. In a 2026 retrospective series of 319 patients from a surgeons' network, the 1-year rate free of functional recurrence for anterior strictures was 78.4% and free of anatomic recurrence 66.4%; recurrence was more likely after hypospadias repair, and the authors describe low effectiveness among high-risk strictures.

Robot-assisted urethroplasty: Robotic approaches for posterior urethral strictures and vesicourethral anastomotic stenosis after radical prostatectomy allow precise endoscopic dissection and reconstruction with reported success rates comparable to open repair in experienced centers, with reduced blood loss and shorter hospital stay.

Patient-reported outcome standardization: The PROM-USS instrument (also written USS-PROM) is being prospectively validated across international multicenter cohorts to enable meaningful comparison of surgical outcomes across institutions and countries — addressing a long-standing criticism that stricture surgery "success" has been defined inconsistently. A 2015 pilot tested a Russian version in 35 men and called for larger studies.

Biomarkers of recurrence: Serum and urinary transforming growth factor beta 1 levels, urethral tissue fibroblast phenotyping, and urine microRNA profiles are under investigation as predictors of stricture recurrence after urethroplasty, potentially enabling personalized adjuvant antifibrotic therapy.

Key Research Papers

  1. Breyer BN, McAninch JW, Whitson JM, Eisenberg ML, Mehdizadeh JF, Myers JB, Voelzke BB. Multivariate analysis of risk factors for long-term urethroplasty outcome. J Urol. 2010;183(2):613-7. — PubMed PMID: 20018318
  2. Buckley JC, Heyns C, Gilling P, Carney J. SIU/ICUD Consultation on Urethral Strictures: Dilation, internal urethrotomy, and stenting of male anterior urethral strictures. Urology. 2014;83(3 Suppl):S18-22. — PubMed PMID: 24286602
  3. Wessells H, Angermeier KW, Elliott S, et al. Male Urethral Stricture: American Urological Association Guideline. J Urol. 2017;197(1):182-190. — PubMed PMID: 27497791
  4. Barbagli G, Kulkarni SB, Fossati N, et al. Long-term followup and deterioration rate of anterior substitution urethroplasty. J Urol. 2014;192(3):808-13. — PubMed PMID: 24533999
  5. Pansadoro V, Emiliozzi P. Internal urethrotomy in the management of anterior urethral strictures: long-term followup. J Urol. 1996;156(1):73-5. — PubMed PMID: 8648841
  6. Andrich DE, Mundy AR. What is the best technique for urethroplasty? Eur Urol. 2008;54(5):1031-41. — PubMed PMID: 18715692
  7. Rourke K, McKinny S, St Martin B. Effect of wound closure on buccal mucosal graft harvest site morbidity: results of a randomized prospective trial. Urology. 2012;79(2):443-7. — PubMed PMID: 22119261
  8. Morey AF, Watkin N, Shenfeld O, Eltahawy E, Giudice C. SIU/ICUD Consultation on Urethral Strictures: Anterior urethra--primary anastomosis. Urology. 2014;83(3 Suppl):S23-6. — PubMed PMID: 24373726
  9. Lumen N, Hoebeke P, Willemsen P, De Troyer B, Pieters R, Oosterlinck W. Etiology of urethral stricture disease in the 21st century. J Urol. 2009;182(3):983-7. — PubMed PMID: 19616805
  10. Mundy AR. Results and complications of urethroplasty and its future. Br J Urol. 1993;71(3):322-5. — PubMed PMID: 8477319
  11. Palminteri E, Berdondini E, Verze P, De Nunzio C, Vitarelli A, Carmignani L. Contemporary urethral stricture characteristics in the developed world. Urology. 2013;81(1):191-6. — PubMed PMID: 23153951
  12. Mangera A, Patterson JM, Chapple CR. A systematic review of graft augmentation urethroplasty techniques for the treatment of anterior urethral strictures. Eur Urol. 2011;59(5):797-814. — PubMed PMID: 21353379
  13. Santucci RA, Joyce GF, Wise M. Male urethral stricture disease. J Urol. 2007;177(5):1667-74. — PubMed PMID: 17437780
  14. Santucci R, Eisenberg L. Urethrotomy has a much lower success rate than previously reported. J Urol. 2010;183(5):1859-62. — PubMed PMID: 20303110
  15. Goulao B, Carnell S, Shen J, et al. Surgical Treatment for Recurrent Bulbar Urethral Stricture: A Randomised Open-label Superiority Trial of Open Urethroplasty Versus Endoscopic Urethrotomy (the OPEN Trial). Eur Urol. 2020;78(4):572-580. — PubMed PMID: 32636099
  16. Shen J, Vale L, Goulao B, Whybrow P, Payne S, Watkin N, OPEN trial investigators. Endoscopic urethrotomy versus open urethroplasty for men with bulbar urethral stricture: the OPEN randomised trial cost-effectiveness analysis. BMC Urol. 2021;21(1):76. — PubMed PMID: 33941140
  17. Oszczudlowski M, Yepes C, Dobruch J, Martins FE. Outcomes of transecting versus non-transecting urethroplasty for bulbar urethral stricture: a meta-analysis. BJU Int. 2023;132(3):252-261. — PubMed PMID: 37402622
  18. Blaschko SD, Sanford MT, Cinman NM, McAninch JW, Breyer BN. De novo erectile dysfunction after anterior urethroplasty: a systematic review and meta-analysis. BJU Int. 2013;112(5):655-63. — PubMed PMID: 23924424
  19. Guralnick ML, Webster GD. The augmented anastomotic urethroplasty: indications and outcome in 29 patients. J Urol. 2001;165(5):1496-501. — PubMed PMID: 11342904
  20. Chi J, Lou K, Feng G, Song S, Lu Y, Wu J, Cui Y. Comparative analysis of holmium: YAG laser internal urethrotomy versus Cold-Knife optical internal urethrotomy in the management of urethral stricture - a systematic review and meta-analysis. Int J Surg. 2024;110(7):4382-4392. — PubMed PMID: 38573099
  21. Jackson MJ, Sciberras J, Mangera A, et al. Defining a patient-reported outcome measure for urethral stricture surgery. Eur Urol. 2011;60(1):60-8. — PubMed PMID: 21419566
  22. Bazaev VV, Shibaev AN, Pavlova YV. [VALIDATION OF THE RUSSIAN VERSION OF THE QUESTIONNAIRE TO ASSESS THE EFFECTIVENESS OF SURGICAL TREATMENT OF PATIENTS WITH ANTERIOR URETHRAL STRICTURE (PATIENT-REPORTED OUTCOME MEASURE FOR URETHRAL STRICTURE SURGERY (PROM-USS): A PILOT STUDY]. Urologiia. 2015;(5):15-9. — PubMed PMID: 26859931
  23. Elliott SP, Coutinho K, Robertson KJ, et al. One-Year Results for the ROBUST III Randomized Controlled Trial Evaluating the Optilume® Drug-Coated Balloon for Anterior Urethral Strictures. J Urol. 2022;207(4):866-875. — PubMed PMID: 34854748
  24. Srikanth P, DeLong J, Virasoro R, Elliott SP. A Drug-Coated Balloon Treatment for Urethral Stricture Disease: Three-Year Results from the ROBUST III Study. J Endourol. 2025;39(9):968-974. — PubMed PMID: 40300835
  25. Patel HV, Erickson BA, Abbasi B, et al. Early Real-World Experience With Optilume Drug-coated Balloon for Anterior Urethral Strictures and Posterior Urethral Stenoses. Urology. 2026;207:233-238. — PubMed PMID: 41109561

↑ Back to Table of Contents

Connections

↑ Back to Table of Contents